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sarah Wilks7, Peter J. Diggle8, Mark Woodhead9,10, Miriam F. Moffatt3, William O. C. Cookson  3 
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the demographics and comorbidities of patients with community acquired pneumonia (CAp) 
vary enormously but stratified treatment is difficult because aetiological studies have failed to 
comprehensively identify the pathogens. our aim was to describe the bacterial microbiota of CAp 
and relate these to clinical characteristics in order to inform future trials of treatment stratified by 
co-morbidity. CAP patients were prospectively recruited at two UK hospitals. We used 16S rRNA 
gene sequencing to identify the dominant bacteria in sputum and compositional data analysis to 
determine associations with patient characteristics. We analysed sputum samples from 77 patients 
and found a Streptococcus sp. and a Haemophilus sp. were the most relatively abundant pathogens. 
the Haemophilus sp. was more likely to be dominant in patients with pre-existing lung disease, and its 
relative abundance was associated with qpCR levels of Haemophilus influenzae. the most abundant 
Streptococcus sp. was associated with qpCR levels of Streptococcus pneumoniae but dominance could 
not be predicted from clinical characteristics. These data suggest chronic lung disease influences the 
microbiota of sputum in patients with CAP. This finding could inform a trial of stratifying empirical 
CAp antibiotics to target Haemophilus spp. in addition to Streptococcus spp. in those with chronic lung 
disease.
The majority of cases of community acquired pneumonia (CAP) are caused by bacteria as demonstrated by the 
dramatic decrease in mortality rates following the introduction of antibiotics1. Aetiological studies of CAP are 
however unable to define a pathogen in half of patients and this proportion falls to less than a quarter in clinical 
practice2,3. Our understanding of the bacterial aetiology of CAP is limited by the practical difficulties in obtain-
ing timely specimens and the selectivity of sputum culture. Aetiological studies have been heavily influenced by 
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positive blood cultures from bacteraemic patients who represent an important, but small, proportion of all those 
with this syndrome. These diagnostic limitations mean most patients receive the same broad spectrum, empirical 
antibiotic treatment despite wide variations in prior comorbidity, prior medications and age. It is likely that the 
bacteria which cause CAP vary in relation to patient characteristics and an understanding of these associations 
would guide stratified prescribing.
Culture independent molecular techniques enable the detection of low abundance and less easily cultured bac-
terial species and some techniques can identify species with greater accuracy than culture. For example Wilkinson 
et al. used PCR of the S. pneumoniae lytA gene to show that 64% of isolates identified as S. pneumoniae using 
traditional methodology following sputum culture had been misidentified and once sequenced were shown to be 
mostly S. pseudopneumoniae4. Respiratory microbiota studies demonstrated that 16S rRNA gene sequencing can 
characterise the bacterial composition of respiratory specimens from healthy subjects and those with respiratory 
disease5,6.
Very few studies have used next generation sequencing to investigate the respiratory microbiota of patients at 
the time of CAP and they have lacked the clinical detail required to advance antibiotic policy7,8. Sputum remains 
the most practical airway specimen in non-ventilated CAP and molecular testing has the potential to surmount 
some of the diagnostic limitations of culture. We determined the microbiota in sputum samples obtained from a 
large series of adults with carefully phenotyped CAP. Our aim was to inform trials of stratified, empiric antibiotic 
therapy by determining how clinical characteristics predict sputum microbiota in this population.
Results
patient characteristics. 169 patients were recruited to the study of whom 86 provided a sputum sample. 
9 samples did not contain mucopurulence and were discarded leaving seventy seven sputum samples to 
be sequenced. The characteristics of those 77 patients are detailed in Table 1. 16.7% of patients had serologi-
cal evidence of a recent influenza infection at the time they presented with CAP. 5/74 (6.8%) of patients grew 
Streptococcus pneumoniae in their blood culture. Chronic lung disease is prevalent among our population and half 
of the cohort self-reported a pre-existing respiratory comorbidity. COPD was three times as common as asthma 
and there was one case of interstitial lung disease (ILD). Radiological or physiological investigations to distin-
guish COPD, asthma and ILD were not performed and since these sub-groups were small, we analysed chronic 
lung disease as a single comorbidity.
Bacteria detected by 16S rRNA gene sequencing. Considering all 77 sequenced sputum samples 
together, 4947 different bacterial operational taxonomic units (OTUs) were detected. The complete data-set is 
available through GenBank accession number PRJEB20580. As anticipated, many OTUs were rare, being found 
in only one sample and had very low relative abundance and we therefore performed the analysis on a sub-set of 
the data with these rare OTUs removed. The final data-set contained 60 OTUs of interest.
Comparing all sputum samples, an airway commensal bacterium of the genus Veillonella spp. (Veillonella_1328) 
was on average the most relatively abundant9. Relative abundance is expressed here as the centred log ratio (clr). The clr 
is a statistically robust method for transforming compositional data in order to compare proportions, and the method 
for calculating the clr is explained in detail in the methods section. A negative clr value means that the OTU is less 
abundant than the mean abundance of all OTUs in that sample; a value of 0 indicates its abundance is the same as the 
mean abundance of OTUs in the sample and a positive value means that it is more abundant than the mean abundance 
of the OTUs in that sample. The second most relatively abundant OTU was a Streptococcus sp. (Streptococcus_4318). 
We compared the relative abundance of this and all other OTUs of the genus Streptococci spp. with the concentration 
of S. pneumoniae in sputum expressed as genome copies per millilitre (mL) and measured by qPCR of the lytA gene. 
Figure 1 shows that the relative abundance of the OTU Streptococcus_4318 was strongly associated with the concen-
tration of S. pneumoniae in each sputum sample; no such association was found with any other Streptococcal OTU.
Similarly, we found a strong association between the most relatively abundant Haemophilus spp. OTU 
(Haemophilus_617) and the concentration of H. influenzae in sputum as measured by qPCR of the Hi-hpd gene 
(Fig. 2). We found no association between the relative abundance of any other Haemophilus spp. OTUs and the 
concentration of H. influenzae in sputum. Since H.influenzae can be difficult to distinguish from H. haemolyt-
icus we compared the relative abundance of the dominant OTU Haemophilus_617 with the concentration of 
H. haemolyticus in sputum as measured by qPCR of the Hh-hpd gene and no association was found. These strong 
associations between species-specific qPCR results and the relative abundance of particular OTUs are highly 
suggestive of, but do not prove, species level identification of these OTUs.
Associations between bacterial composition of sputum and patient characteristics. We used 
multivariate analysis of variance (MANOVA) to determine if clinical characteristics known on admission were 
associated with different patterns of bacteria in the sputum (Table 2). Chronic lung disease had the only signif-
icant association (P = 0.03) on the bacterial composition of sputum (shown graphically Fig. 3). To determine 
which bacteria made the greatest contribution to the differences in bacterial composition we conducted a princi-
pal components analysis of the OTUs found in sputum. Figure 4 shows that Haemophilus_617 was responsible for 
driving much of the variation in sputum composition among this cohort, with the OTU being dominant in some 
samples and only a minor component of others.
Having so far shown above that a) the composition of bacteria in sputum varied in association with clinical 
characteristics and b) the OTU Haemophilus_617 was responsible for the greatest proportion of this variation 
in bacterial composition we next sought to determine which bacteria were responsible for the specific composi-
tional changes seen in sputum from patients with chronic lung disease. We used Fischer’s exact test to determine 
whether the relative abundance of OTUs were associated with the presence or absence of chronic lung disease. 
Patients with chronic lung disease were more likely to have a high relative abundance of Haemophilus_617 
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than those without chronic lung disease (OR = 5, CI 1.2–29.6, P = 0.015). No other bacterial OTU was statis-
tically significantly associated with presence or absence of chronic lung disease. Figure 5 illustrates this find-
ing and demonstrates that sputum from patients with chronic lung disease was more likely to be dominated by 
Haemophuilus_617 than sputum from patients without lung disease.
Discussion
We have conducted an innovative and detailed study of adult sputum microbiota in patients with acute com-
munity acquired pneumonia. The factor which had the greatest effect on the bacterial composition of sputum 
from adults with CAP was the presence of chronic lung disease. Modern molecular techniques gave compelling 
evidence that sputum from patients with chronic lung disease was more likely to be dominated by Haemophilus 
influenzae than by other bacteria. A Streptococcus OTU was the second most relatively abundant bacteria in these 
sputum samples and associated with the level of Streptococcus pneumoniae. However, whilst this Streptococcus 
was frequently the dominant pathogen, its relative abundance could not be predicted by patient characteristics.
The key strength of this study is that our patients were rigorously characterised using an extensive range of 
clinical and laboratory parameters. We used compositional sequence analysis without rarefaction, comparing 
proportions rather than absolute read counts, thus avoiding the associated false-positive conclusions10,11. It was 
Characteristic
N = 77 (except 
for*)
Age (years), median (IQR) 68 (49–76)
Male, N (%) 42 (55.3)
*Smoking status, N (%)
Active 38 (50.7)
Quit 27 (36)
Never 10 (13.3)
Charlson Comorbidity 
Index, N (%)
0 23 (30.3)
1 32 (42.1)
2 8 (10.5)
3 10 (13.2)
4 2 (2.6)
5 1 (1.3)
6 0
Prior pulmonary disease
Any, N (%) 46 (59.7)
COPD, N (%) 35 (45.5)
Asthma, N (%) 10 (13.0)
Other, N (%) 1 (1.3)
CURB65, N (%)
0 22 (28.6)
1 13 (16.9)
2 23 (29.9)
3 18 (23.4)
4 1 (1.3)
5 0
Prior statin use, N (%) 23(29.9)
*CRP (mg/ml), median (IQR) 147 (78.8–230.2)
*PCT (ng/ml), median (IQR) 0.77 (0.18–4.15)
*BMI (Kg/m2), median (IQR) 25.9 (22.3–30.2)
*Influenza infection, N (%) 9 (16.7)
*Pneumococcal bacteraemia, N (%) 5 (6.8)
Prior antibiotics, N (%) 7 (9.1)
In hospital mortality, N (%) 2 (2.6)
Length of stay (days), median (IQR) 5 (4.0–8.0)
30 day re-admission, N (%) 8 (10.4)
Table 1. Patient characteristics. The Charlson comorbidity index is a tool for predicting the risk of mortality 
during admission that is attributable to pre-existing comorbid conditions. CURB-65 is a validated tool for 
predicting risk of 30 day mortality from CAP. The components are C = confusion (present scores 1, absent 
scores 0), U = urea (>7 mmol/L scores 1, ≤7 mmol/L scores 0) R = respiratory rate (≥30 scores 1, <30 scores 
0) B = Blood-pressure (systolic <90 mmHg or diastolic ≤60 mmHg score 1) and age (≥65 years scores 1, <65 
years scores 0). CRP is serum C-reactive protein level, <5 mg/mL is normal. PCT is serum procalcitonin level, 
serum levels >5 ng/mL are strongly associated with bacterial infection and this is the threshold for antibacterial 
treatment being ‘strongly recommend’43. BMI is body mass index. Prior antibiotics records the number of 
patients who had been taking antibiotics in the community for greater than 24 hours prior to admission. *Data 
was incomplete for variables marked with an asterisk: Smoking status N = 74, CRP N = 76, PCT N = 69, BMI 
N = 67, Influenza N = 54 and Pneumococcal bacteraemia N = 74.
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Figure 1. Correlation between the relative abundance of Streptococcal OTU_4318 and the concentration 
of S.pneumoniae in sputum. Here we compare, on the y axis, the relative abundance of the Streptococcal 
OTU_4318 in each sputum sample (expressed as the centred log ratio (clr)) with, on the x axis, the 
concentration of Streptococcus pneumoniae (S. pneumoniae) in genome copies/mL as measured by qPCR of the 
lytA gene.
Figure 2. Correlation between the relative abundance of Haemophilus OTU_617 and the concentration of 
H.influenzae in sputum. Here we compare, on the y axis, the relative abundance of the Haemophilus OTU_617 
in each sputum sample (expressed as the centred log ratio (clr)) with, on the x axis, the concentration of 
Haemophilus influenzae (H. influenzae) genome copies/mL as measured by qPCR of the Hi-hpd.
Variable P
Chronic lung disease 0.03
Pro-calcitonin 0.14
Neutrophil count 0.15
Age 0.18
Prior statin use 0.18
Body mass index 0.19
Smoking 0.36
CURB-65 score 0.40
Charlson comorbidity index 0.42
C-reactive protein 0.59
Index of multiple deprivation 0.71
Influenza 0.78
Gender 0.92
Prior antibiotics Not tested
Table 2. Associations between clinical variables and the bacterial composition of sputum in CAP. The table 
shows the results of a Multivariate analysis of variance (MANOVA). P values are the result of the Wilks Lambda 
test comparing the variation in the relative abundance of all 60 bacterial OTUs (dependent variables) between 
clinical groups (independent variables e.g. gender). Too few patients had received pre-hospital antibiotics to 
perform a valid statistical test.
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not our intention to evaluate the use of such sequencing techniques in clinical practice but rather to apply this 
platform to better understand how the community structure of sputum varies in CAP in association with par-
ticular patient characteristics. This is the first microbiota study to demonstrate how a particular patient charac-
teristic – the presence of lung disease – has an appreciable association with the bacterial community structure of 
sputum in patients with CAP. The relevance of this finding is that is can be tested by a randomised controlled trial 
since the taxonomic group driving the community structure, Haemophilus spp., suggests a particular therapeutic 
option.
Our cohort had similar characteristics to other prospectively recruited UK CAP cohorts12 however we 
excluded patients with malignancy and advanced dementia and it would be worth investigating individuals with 
these conditions. Moreover, these results only apply to patients with CAP who produce sputum and future stud-
ies should attempt to describe the bacterial microbiota in non-expectorating adult patients by bronchoalveolar 
lavage or percutaneous aspiration of consolidated lung13. Many sputum samples were dominated by a single 
highly abundant species suggesting pathogenic overgrowth and implying causality, but the link between relative 
abundance and causality is not straightforward and some invasive bacteria may be able to cause disease at lower 
relative abundance than others. Establishing causation with certainty may not be possible but testing the hypoth-
esis that some bacteria are more likely to be the cause than others in certain contexts could be tested by large 
randomised controlled trials of different antibiotic regimes. The association of the dominant Haemophilus OTU 
with qPCR levels of H. influenzae is not proof of species identification but in the context of the known association 
between Nontypeable Haemophilus influenzae (NTHi) and lung disease this correlation is highly suggestive14.
Some have questioned the utility of a molecular analysis of sputum for the study of CAP on the basis of 
potential ‘contamination’ by upper airway bacteria. However, owing to the close correlation between bacterial 
populations at the two sites, several authors have recently shown that molecular analysis of sputum can provide 
valuable diagnostic information in CAP15–17. Further, we agree with the conceptual model expounded by Dickson 
et al. who highlight that, given the anatomical continuity of the respiratory tract, there are no rigid upper and 
lower tract communities as bacteria constantly transition throughout18. During pneumonia, conditions in the 
lung change in such a way as to enable certain bacteria to flourish. In this context, sputum remains a valid sample 
for analysis and features in all contemporary CAP clinical guidelines.
In current clinical practice, the culture of H. influenzae or S. pneumoniae from purulent sputum provided by a 
patient presenting with CAP, would be regarded as diagnostic and the patient would receive targeted antibiotics – 
despite the fact that both bacteria are known to colonise the upper airway of asymptomatic individuals. Moreover, 
the bacterial culture results reported by a clinical laboratory do not include all bacteria grown but mention only 
those felt to be relevant based on relative speed and quantity of growth on a range of media. The clinical culture 
report is therefore based on interpreting the range of cultured bacteria on the basis of relative abundance and in 
the light of the clinical context. This is the rationale we have applied to the interpretation of causality with our 
sequencing results.
Figure 3. The bacterial composition of sputum samples from patients with CAP differ in the presence or 
absence of chronic lung disease. This plot enables us to visually compare the extent to which the bacterial 
composition of sputum samples differ. The axes are the first two principal components of variation in the 
bacterial composition of these sputum samples. The axes have no units. Black dots are sputum samples from 
patients with chronic lung disease and grey dots are sputum samples from patients without chronic lung disease. 
The ellipses encompass 75% of samples from each group and show those from patients with chronic lung 
disease were more closely related to one another, with a tight cluster in the top right quadrant, than those from 
patients with no prior lung disease. This suggests there was a bacterium or bacteria whose relative abundance 
was frequently similar in patients with chronic lung disease.
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We identified patients who were infected with influenza virus at the time of their CAP, but did not find an 
association with the relative abundance of any particular bacterial OTU. Although our primary aim was to inves-
tigate the bacteria in CAP we chose to detect influenza virus and include it as a variable since the association 
between influenza infection and risk of development of secondary bacterial CAP is well known. In recent studies 
molecular testing has demonstrated a broad range of viruses can be detected at the time of CAP, particularly in 
children, although their role in the disease is unclear3. Future studies designed to investigate the role of viruses in 
CAP could replicate our analysis to determine if there are associations between particular viruses and bacterial 
OTUs in CAP.
Figure 4. The relative abundance of bacterial OTUs in sputum. The axes are the same as in Fig. 3, but 
here we compare the extent to which the relative abundance of individual OTUs varies in this data-set. 
Each dot is a unique bacterial OTU. Certain OTUs, from genera known to cause pneumonia, have been 
labelled by the genus to which they belong (see key below). The position of each OTU on the plot gives an 
indication of how its relative abundance in samples varies. Those which are close to the origin, where the 
dashed-lines intersect, have a similar relative abundance in all samples (zero variance). Those which are 
far away from the origin are much more abundant in some samples than others. OTUs which are distant 
from one another, for example Haemophilus_617 and Prevotella_956, have a reciprocal pattern of relative 
abundance such that when one is high the other is low. OTUs which are close e.g. Pseudomonas_3976, 
Moraxella_2510 and Klebsiella_1954 all tend to have a higher relative abundance in the same sample. Key: 
Fuso = Fusobacterium_1252. Prev = Prevotella_956. Veil = Veillonella_1328. Gran = Granulicatella_740. 
Neis = Neisseria_4683. Acti = Actinomyces_3641. Pseu = Pseudomonas_3976. Mora = Moraxella_2510. 
Kleb = Klebsiella_1954. Lact = Lactobacillus_2480. Haem = Haemophilus_617. Str_1 = Streptococcus_4318. 
Str_2 = Streptococcus_1024. Str_3 = Streptococcus_360.
Figure 5. During CAP, a Haemophilus sp. is the most frequently dominant OTU in sputum from patients with 
chronic lung disease. In this histogram the height of each column represents the number of times a particular 
bacterial OTU was the most relatively abundant (dominant) OTU sequenced from sputum. Patients are divided 
into those with and without chronic lung disease.
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In comparison with the existing literature, the spectrum of bacteria identified with high relative abundance 
in this study was consistent with prior descriptions of pneumonia in high income countries suggesting that, the 
high rate of negative pathogen identifications in previous CAP studies is unlikely to be explained by a previously 
uncultured bacteria. Two smaller studies have previously studied sputum microbiota in CAP. Chen et al. analysed 
sputum from 45 Chinese CAP patients and compared them to saliva samples from healthy subjects and sputum 
from a separate cohort with hospital acquired pneumonia7. Their proof of concept study described differences 
between disease and health but had limited clinical applicability. Mizrahi et al. analysed sputum from 21 Israeli 
patients in critical care, however limited clinical information was provided and the diagnostic criteria for pneu-
monia were not defined8.
Regarding rates of pneumococcal identification, Said et al. estimated that for every case of pneumococcal 
bacteraemic CAP there are another 3 non-bacteraemic cases and that S. pneumoniae is responsible for 25% of 
all CAP cases19. This estimate fits our data where, of the 77 patients with sequenced sputum, five grew S. pneu-
moniae in the blood implying an additional fifteen non-bacteraemic cases giving an estimate of 20/77 = 25% of 
cases. Two important bacterial causes of CAP were not identified in our samples: Legionella pneumophila and 
Chlamydophylla pneumoniae. We used mechanical DNA extraction in order to detect intracellular bacteria and 
two members of the intracellular genus Mycoplasma were detected, at low relative abundance, so we are confident 
that if other intracellular bacteria had been present at a clinically meaningful levels of relative abundance they 
would have been detected.
Our data suggest that a Haemophilus sp. may be a more common cause of CAP in adults with chronic lung 
disease than has hitherto been appreciated. This is a view supported by several recent influential reviews14,20. If 
this finding were validated it would have implications for clinical efficacy and antimicrobial stewardship because 
current empirical CAP antibiotic regimens for non-severe CAP focus on beta-lactam/macrolide combinations 
and this provides sub-optimal cover for Gram-negative respiratory infections. If validated our data suggest dox-
ycycline or a respiratory fluoroquinolone may be a better first line choice for those with non-severe CAP and 
chronic lung disease. This is supported by recent observational data from Spain where Nontypable Haemophilus 
influenzae (NTHi) resistance to beta-lactams was 23.2%21 and German data showing 11% more treatment failures 
in non-severe H. influenzae pneumonia treated with beta-lactam monotherapy compared to a tetracycline or 
fluoroquinolone22.
In conclusion, in hospitalised adults with non-severe CAP, the presence of chronic lung disease predicts the 
frequent dominance of a Haemophilus sp. These results alone should not be used to change practice but should 
inform a randomised trial comparing a standard empirical antibiotic regime with another expanded to cover 
Nontypable Haemophilus influenzae in patients who develop CAP on a background of chronic lung disease.
Methods
patients. Between February 2011 and March 2013 we recruited consecutive patients aged ≥16 years with 
CAP (British Thoracic Society definition23) from two hospitals in Liverpool, UK. We excluded patients admitted 
within the last 14 days, with Cystic Fibrosis (CF) or non-CF bronchiectasis, who were immunocompromised, 
mechanically ventilated, required renal replacement therapy, or had either thoracic malignancy or advanced can-
cer of any type, those who were treated palliatively and those with severe cognitive impairment.
ethics and regulatory compliance statement. This work was approved by the UK NHS Research Ethics 
Committee (NHS REC Number 10/WNo03/40) and was listed on the NIHR Clinical Research Network portfolio. 
All subjects provided informed consent and, in accordance with the UK mental capacity act, a consultee provided 
assent on behalf of those who lacked capacity as a consequence of CAP related delirium - with consent being 
retrospectively obtained upon recovery of capacity. All aspects of the research were conducted in accordance with 
local and national policies as articulated by the UK Research Governance Framework for Health and Social Care 
2005.
In-hospital management and study procedures. The study team had no role in clinical manage-
ment which was part of a regional pneumonia performance audit24. Recruitment and sampling occurred within 
24 hours of the first dose of in-hospital antibiotic. Sputum was expectorated into sterile (pre-sealed and UV irra-
diated) pots and frozen immediately to −85 °C without further processing. Only samples with obvious mucop-
urulence were stored – those which appeared to be predominantly salivary were discarded. We recorded clinical 
variables which may predict different patterns of sputum bacteria e.g. socioeconomic status (see below), the 
Charlson comorbidity index25, body mass index (BMI), pro-calcitonin, C-reactive protein, neutrophil count, age, 
prior-medications, influenza infection and the CURB-65 score [C (confusion) U (Urea) R (Respiratory rate) B 
(blood pressure) age over or under 65 years)]26.
socioeconomic status. Previous studies have suggested socioeconomic status is a risk factor for the devel-
opment of CAP. We used the Index of Multiple Deprivation (IMD) to describe socioeconomic deprivation and 
tested if socioeconomic status was an independent predictor of the pattern of bacteria present in sputum during 
CAP. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/465791/English_Indices_
of_Deprivation_2015_-_Statistical_Release.pdf
Influenza serology. Serum samples were analysed by haemagglutination inhibition for the following influ-
enza viruses: B/Brisbane/60/2008, B/Wisconsin/1/2010, A/Perth/16/2009(H3N2), A/Victoria/361/2011 (H3N2), 
A/California/7/2009(H1N1) as previously described27 with minor modifications: using 4 haemagglutinating units 
(4HAU) and 0.5% guinea pig for influenza H3N2 and 0.5% turkey erythrocytes for influenza B and A(H1N1)
www.nature.com/scientificreports/
8Scientific RepoRts |          (2019) 9:2388  | https://doi.org/10.1038/s41598-018-38090-5
pdm09. Serum samples were tested in duplicate at an initial dilution of 1:10 and a final dilution of 1:1280. Suitable 
control serum samples were included in all analyses; post-infection ferret serum samples raised against the five 
vaccine strains used in the analysis, served as positive controls, and human serum samples from individuals with 
either high antibody titres to currently circulating influenza H1, H3, and B strains or from individuals with no 
antibody titres to these seasonal strains were used as positive and negative controls, respectively. Patients were 
recorded as having CAP associated with an influenza infection if they had a 4 fold rise in their influenza titre 
between admission and follow-up.
DNA extractions. Sputum samples were defrosted in batches and DNA was mechanically extracted using 
an MPBio FastPrep®-24 bench-top homogeniser and FastDNA™ SPIN Kits for Soil (MPBio http://www.mpbio.
com/product.php?pid=116560200) in accordance with the manufacturer’s instructions.
16S rRNA gene pyrosequencing and 16S rRNA gene quantitative PCR. Polymerase chain 
reactions (PCR) of the V3-V5 regions of the 16S rRNA gene were performed using Q5® High Fidelity Master 
Mix (New England BioLabs Inc.) in a 25 µl PCR including 1 µl of template DNA, 1 µl forward primer 357 F 
(5′CCGTCAATTYMTTTRAGT3′) and 1 µl reverse primer 926 R (5′CCTACGGGAGGCAGCAG3′). A positive 
and a negative PCR control was included in all PCRs and extraction kit controls were included. Reaction steps for 
the 16S rRNA PCRs were: −95 °C for 2 minutes then 35 cycles of 95 °C for 20 seconds then 50 °C for 30 seconds 
then 72 °C for 5 minutes. Four replicates of each polymerase chain reaction (PCR) were pooled to improve the 
detection of low abundance OTUs28. Once pooled the final dsDNA amplicon concentrations from each sample 
were quantified using the Quant-iT™ kit (Invitrogen) according to the manufacturer’s protocol. Equimolar con-
centrations of amplicon from each sample were then collected into a single tube creating an admixture of PCR 
products from all sputum samples. This meta-sample was then purified using Agencourt® AMPure® XP bead kits 
before being re-quantified using Quant-iT™ (Invitrogen). The purified amplicon pool underwent pyrosequencing 
on a 454 Life Sciences GS FLX (Roche Diagnostics, Oakland, CA) as per the manufacturer’s protocol. 16S rRNA 
gene qPCRs used the 357 F and 926 R primers (as above) in 10 ml triplicate quantitative PCRs (qPCRs) incorpo-
rating KAPA SYBR FAST Universal 23 qPCR master mix (Kapa Biosystems, Woburn, MA), and analysed the data 
with Corbett rotor-gene 6.1 software (Qiagen, Venlo, the Netherlands) as previously published29.
Analysis of sequence data. Pre-processing of the raw sequencing data was performed using the 
Quantitative Insights into Microbial Ecology (QIIME) pipeline for analysis30. Within QIIME AmpliconNoise was 
used to de-noise and de-multiplex the samples and Perseus removed chimeras31. Operational taxonomic units 
(OTUs) were assigned by clustering sequences at a 97% identity threshold in UCLUST program and the most 
abundant sequence within an OTU cluster was chosen as the representative sequence for that OTU32. The Silva 
SSU Ref ND database (version 111) was used for taxonomical assignment of each OTU by using an 80% bootstrap 
confidence around a representative sequence from each OTU33. PyNAST was used for alignment of representative 
sequences by accessing the Silva reference set34. FastTree was used for phylogenetic tree reconstruction from a 
representative sequence of each OTU35.
Subsequent analyses involving assigned OTUs were performed in R (ver3.3.2) using the compositional analy-
sis package CoDaSeq (https://github.com/ggloor/CoDaSeq). For each sample, sequence read counts were trans-
formed by taking the log of the ratio of the count for an OTU and the geometric mean of the counts of all OTUs in 
that sample; this transformation is termed the centred log ratio (clr)36. The clr values use log 2; a clr of 5 therefore 
means the OTU was 32 fold more abundant than the mean abundance of all OTUs in that sample. High through-
put sequencing data is ‘sparse’ meaning it contains many zeros as a consequence of rare bacteria. Methodologies 
for handling sparse data are an area of ongoing research but we chose to replace zeros using a Bayesian approach 
using the “CZM” method of the ‘cmultRepl’ function within the R package zCompositions37. Since our aim was 
to study how variation in bacterial composition might relate to clinical covariates such as comorbidity, we filtered 
the data to remove non-informative OTUs whose clr value varied between samples less than the median variance 
of all OTUs; the clr transformation permits this approach by preserving correlation and variance properties when 
the data is sub-set10. This work was performed concurrently with the work of Salter et al. who demonstrated that 
commercial DNA extraction kits may be contaminated by bacterial DNA leading to spurious conclusions unless 
accounted for; as a consequence extraction kit controls were included in our sequencing runs38. We observed 
contaminating OTUs associated with the DNA extraction kit used on a particular date and this was most obvious 
in low biomass samples from another study. Given that similar extraction kits were used for the sputum samples 
in this study a sensitivity test was performed by repeating the planned analysis with and without those potentially 
contaminating OTUs; the inclusion or exclusion of these OTUs had no effect on the associations between OTUs 
and clinical characteristics nor on the relative abundance of OTUs. Principal components analysis (PCA) was 
used to explore which samples were compositionally similar and which clinical characteristics explained any 
clustering of samples. Multivariate analysis of variance (MANOVA) along with the Wilks lambda test was imple-
mented to determine statistical significance of observed differences.
Pathogen specific quantitative PCR (qPCR). For certain genera 16S rRNA gene amplicon sequenc-
ing, due to high levels of homology, is unable to discriminate to the level of individual species. As this 
was the case for both Streptococcus spp. and Haemophilus spp., genera that contain important respira-
tory pathogens, quantitative PCRs (qPCRs) were performed39. Detection and quantification of S. pneumo-
niae DNA was performed by lytA qPCR using the following primer and probe sequences: forward primer, 
5′-ACGCAATCTAGCAGATGAAGCA-3′; reverse primer, 5′-TCGTGCGTTTTAATTCCAGCT-3′; probe, 
5′-(6-FAM)-TGCCGAAAACGCTTGATACAGGGAG-(BHQ-1®)-3′. Each PCR reaction contained 12.5 ul of 
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Taqman gene expression mastermix (Applied Biosystems, California, USA), 900 nM of each primer, 500 nM of 
the probe and 2.5 ul of extracted DNA and the standard curve consisted of six serial dilutions (106–101) of lytA 
plasmid (Fast-Track Diagnostics, Slierna, Malta). Thermal cycling was performed in a StepONE system (Applied 
Biosystems) under the following conditions: 10 min at 95 °C followed by 40 cycles of 15 sec at 95 °C and 1 min at 
60 °C.
Haemophilus influenzae DNA was detected and quantified by qPCR of the H. influenzae hpd gene (Hi-hpd) 
using the hpd#3 PCR of Wang et al.40 with the following modifications: both primers were used at a concentration 
of 300 nM and the probe was labelled with FAM dye and BHQ1 quencher; the PCR was duplexed with an inhi-
bition detecting positive control based on Murphy et al.41. This comprised the published gfpF and gfpR primers, 
published gfp probe labelled with CY5 dye and BHQ2 quencher, plus purified genomic DNA from an E. coli strain 
engineered to carry the gfp gene from Aequorea victoria (E. coli BLR-GFP). Each final PCR reaction contained 
Taqman Universal PCR master Mix (Applied Biosystems, UK), 300 nM each of hpdF822 and hpdR952 primers, 
100 nM hpdPb896i (FAM/BHQ1) probe, 150 nM each of gfpF and gfpR primers, 200 nM gfp (CY5/BHQ2) probe, 
1 pg E. coli BLR-GFP DNA, plus 2 µl of sample DNA extract in a final volume of 25 µl. PCR was performed on 
a 7500 Fast Real-Time PCR System (Applied Biosystems, UK) using the manufacturer’s recommended cycling 
conditions. Ct values were converted to DNA concentrations using a standard curve of purified H. influenzae 
genomic DNA (Vircell, Spain) spanning 2.5 to 10000 genome copies/µl.
Haemophilus haemolyticus was detected and quantified by qPCR specific for the H. haemolyticus hpd gene 
(Hh-hpd) using a variation of the method of Latham et al.42. Each 20 µl reaction contained PowerUp SYBR Green 
Master Mix (Applied Biosystems, UK), 300 nM of Hh-hpd F and Hh-hpd R primers. PCR was performed on a 
7500 Fast Real-Time PCR System (Applied Biosystems, UK) using the manufacturer’s recommended cycling 
conditions. Ct values were converted to DNA concentrations using a standard curve of purified H. haemolyticus 
(NCTC10659) genomic DNA spanning 10 to 10000 genome copies/µl. The H. haemolyticus genomic DNA was 
prepared using the QIAsymphony SP automated instrument (QIAGEN), quantified using the Qubit dsDNA BR 
Assay Kit (Life Technologies, Paisley, UK) and converted to genome copies/µl using a value of 2.0fg/genome.
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